​Salesforce, Inc. (NYSE:CRM) is one of the Best Quality Stocks to Buy Before 2026. On December 17, Salesforce, Inc. (NYSE:CRM) announced that Novartis (NYSE:NVS) has selected the company’s Agentforce Life Sciences for Customer Engagement to connect patients and Healthcare professional experiences. ​Novartis has already invested in the company through Agentforce Health, 360 for Health & Life Sciences, MuleSoft for Life Sciences, and Agentforce Marketing. Now it plans to unify the engagement across marketin ...

​Salesforce, Inc. (NYSE:CRM) is one of the Best Quality Stocks to Buy Before 2026. On December 17, Salesforce, Inc. (NYSE:CRM) announced that Novartis (NYSE:NVS) has selected the company’s Agentforce Life Sciences for Customer Engagement to connect patients and Healthcare professional experiences. ​Novartis has already invested in the company through Agentforce Health, 360 for Health & Life Sciences, MuleSoft for Life Sciences, and Agentforce Marketing. Now it plans to unify the engagement across marketin ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 在 前列腺癌 中，雄激素受体 （AR） 通路强效抑制剂 （例如 恩杂鲁胺 ） 初始治疗效果显著，但通常难免产生耐药性。 近日，哥伦比亚大学 Michael M. Shen 团队与 Chao Lu 团队合作，在国际顶尖学术期刊 Nature 上发表了 题为： NSD2 targeting reverses plasticity and drug resistance in prostate cancer 的研究论文。 该研究表明， NSD2 靶向治疗可逆转 前列腺癌 的可塑性和耐药性。NSD2 与 AR 的双靶向治疗策略，有望为当前缺乏有效治疗手段的致死性 去势抵抗性前列腺 癌 （CRPC） 亚型提供新的治疗途径。 谱系可塑性是驱动恶性肿瘤进展及治疗耐药性的关键特征。这种可塑性通常由具备可逆潜能的表观遗传机制介导，但临床实践中实现逆转的案例极为罕见。 在 去势抵抗性前列腺癌 （ castration-resistant prostate cancer， CRPC） 中，肿瘤可塑性介导了对雄激素受体 （AR） 抑制剂的耐药性，并促使腺癌向 神经 内分泌前列腺癌 （CRPC- ...

Group 1 - Capital is increasingly directed towards high-growth AI companies, leading to a neglect of other investment opportunities due to the prevailing AI trend in the markets [1] - There is a concern regarding a potential patent cliff, which refers to the loss of revenue from drugs that are going off-patent [1] Group 2 - The article emphasizes the importance of combining top-down macro analysis with bottom-up stock selection to identify mispriced opportunities in the market [1] - The focus areas include earnings, technological disruption, policy shifts, and capital flows, which are critical for investment decision-making [1]

Group 1 - Capital is increasingly directed towards high-growth AI companies, leading to a neglect of other investment opportunities due to the prevailing AI trend in the markets [1] - There is a concern regarding a potential patent cliff, which refers to the loss of revenue from drugs that are going off-patent, impacting pharmaceutical companies [1] Group 2 - The article emphasizes the importance of combining top-down macro analysis with bottom-up stock selection to identify mispriced opportunities in the market [1] - It highlights the focus on earnings, technological disruption, policy shifts, and capital flows as key factors in investment decision-making [1]

Asian shares were mixed Thursday in thin holiday trading, with most markets in the region and elsewhere closed for Christmas.In Tokyo, the Nikkei 225 edged 0.1 per cent higher to 50,407.79. It has gained nearly 30 per cent this year.The dollar slipped to 155.85 Japanese yen from 155.94 yen. The euro climbed to US$1.1786 from US$1.1780.Markets in mainland China advanced, with the Shanghai Composite index up 0.5 per cent at 3,959.62. Hong Kong’s exchange was closed.Investors were encouraged by a statement by ...

Core Insights - Rezolute, Inc. experienced a significant decline in its stock price following disappointing results from its Phase 3 sunRIZE clinical trial for its lead drug candidate, ersodetug, which failed to meet primary and key secondary endpoints [4][5] Group 1: Company Overview - Rezolute, Inc. is publicly traded on NASDAQ under the ticker RZLT [2] - The company is focused on developing treatments for congenital hyperinsulinism [4] Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug did not achieve statistically significant reductions in hypoglycemia events compared to placebo [4] - The highest dose in the trial showed reductions that were not statistically significant [4] Group 3: Stock Performance - On December 11, 2025, Rezolute's stock price plummeted from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [5] - Trading was halted under Nasdaq's volatility controls due to the drastic decline [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4].

Core Insights - The article discusses the rising popularity of glucagon-like peptide-1 (GLP-1) agonists, particularly Ozempic, as effective weight management solutions for individuals struggling with obesity and diabetes [1][3][4]. Group 1: Ozempic Overview - Ozempic is an injectable medication primarily used for managing blood sugar levels in adults with type 2 diabetes, but it has gained attention for its potential weight loss effects [7][22]. - The active ingredient in Ozempic, semaglutide, is FDA-approved in higher doses for treating obesity under the name Wegovy [7][26]. - Ozempic is administered once a week via a pre-filled pen injector, making it a long-acting option compared to other diabetes medications [23]. Group 2: Weight Loss Efficacy - Clinical trials indicate that individuals taking Ozempic can experience weight loss, with an average loss of approximately 8 lbs over 30 weeks at a 0.5 mg dose, and up to 15 lbs at a 2 mg dose over 40 weeks [39][40]. - Wegovy, with a higher dosage of 2.4 mg, has shown that individuals can lose 10% of their initial body weight in the first 20 weeks [41]. - The weight loss effects of semaglutide are attributed to its ability to modulate hunger centers in the brain and slow gastric emptying, leading to reduced appetite and prolonged feelings of fullness [28][27]. Group 3: Market Demand and Shortages - The popularity of Ozempic has led to shortages as demand increases, particularly for off-label use in weight loss among individuals without diabetes [3][34]. - The high demand for Wegovy has also resulted in significant availability issues, prompting many to seek Ozempic as an alternative [34]. Group 4: Alternative Solutions - PhenQ is presented as an alternative weight loss supplement that claims to suppress cravings and assist in fat loss, although it is not a direct substitute for Ozempic [12][25]. - The article highlights the importance of lifestyle modifications, including diet and exercise, to maximize the benefits of medications like Ozempic and Wegovy [42].

Core Viewpoint - AbbVie has shown strong financial performance and growth potential, making it an attractive investment option heading into 2026 [2][3][11] Financial Performance - AbbVie's revenue increased by 8% year over year to $44.5 billion in the first nine months of the year [3] - Adjusted earnings per share declined to $7.29 from $7.96, primarily due to acquisition-related charges, but this is not a major concern [3] - The company projects high single-digit revenue growth through 2029, indicating sustained financial momentum [3] Growth Drivers - AbbVie has revised its 2027 sales projections for Skyrizi and Rinvoq, increasing it by $4 billion, which are key growth drivers [5] - Other contributors to growth include Vraylar for schizophrenia and Qulipta for migraines [6] - Humira, despite losing patent exclusivity, generated $3.3 billion in sales in the first nine months of 2025, although its revenue declined by 55% year over year [6] Challenges - The U.S. government has targeted Vraylar for drug price negotiations, effective in 2027, but management does not expect significant long-term impacts [7] - AbbVie anticipates no loss of patent exclusivity for major growth drivers through the end of the decade [7] Valuation and Dividend - AbbVie is trading at 16.1 times forward earnings, below the healthcare sector average of 18.2, suggesting reasonable valuation [9] - The company's PEG ratio is currently 0.4, indicating that shares are undervalued [10] - AbbVie has a strong dividend program, with a forward yield of 3% and a cash payout ratio of 61.8%, making it a Dividend King with 54 consecutive annual dividend increases [10][11]